|
Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Clinical research trials and Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors. Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors clinical trial. Participants oftentimes recieve the most expert healthcare available for their Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "F" Clinical Trials Conditions > Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors  Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors
Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors
For Condition: metastatic gastrointestinal carcinoid tumor,recurrent gastrointestinal carcinoid tumor,pulmonary carcinoid tumor
Status: Completed
Sponsor(s): Mid-Atlantic Oncology Program , Cancer Biotherapy Research Group
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of the cancer cells. Combining interferon alfa with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of fluorouracil plus interferon alfa in treating patients who have advanced metastatic carcinoid tumors.
Details: OBJECTIVES: - Determine the objective response rate and duration of remission in patients with advanced metastatic carcinoid tumors treated with fluorouracil and interferon alfa-2b. - Determine the symptomatic response in patients treated with this regimen. - Determine the toxicity of this regimen in these patients. - Determine the quality of life of patients treated with this regimen. - Determine the survival characteristics of patients treated with this regimen. OUTLINE: Patients receive fluorouracil IV continuously for 10 weeks and interferon alfa subcutaneously 3 times a week for 12 weeks. Treatment continues every 12 weeks in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and at weeks 1, 7, and 11 of each course. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically proven carcinoid tumor with radiologically confirmed metastatic disease - Recurrence after surgery or radiotherapy allowed - Must meet at least 1 of the following conditions: - Symptomatic carcinoid syndrome not controlled - Other systemic symptoms (e.g., weight loss, anorexia) - 24 hour urinary 5-hydroxyindole acetic acid (5-HIAA) 100 mg or greater - Bone metastases - Carcinoid heart disease - Carcinoid asthma - Measurable disease or 24-hour urinary 5-HIAA 50 mg or greater required - No known brain metastases PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Zubrod 0-2 Hematopoietic: - Granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 3.0 mg/dL Renal: - Creatinine no greater than 2.0 mg/dL Cardiovascular: - See Disease Characteristics Pulmonary: - See Disease Characteristics Other: - No concurrent infection (no fever for at least 3 days prior to treatment unless fever due to tumor) - No significant medical or psychiatric illness that would preclude study or informed consent - No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or curatively treated stage I carcinoma of the cervix - Not pregnant - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior interferon therapy Chemotherapy: - No other concurrent chemotherapy Endocrine therapy: - Prior endocrine therapy allowed - Concurrent octreotide allowed Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior radiotherapy - No concurrent radiotherapy Surgery: - See Disease Characteristics - Prior surgery allowed Other: - No prior fluorinated pyrimidine
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JamesAhlgren, Study Chair, George Washington University
George Washington University Medical Center
Washington D.C., District of Columbia, 20037
United States
Additional Information:
Study ID Numbers: CDR0000076667; MAOP-5190,NBSG-9010,NCI-V90-0197
Study Start Date:
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002470
Other Metastatic Gastrointestinal Carcinoid Tumor Studies:
1. Bevacizumab and PEG-Interferon alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
2. Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors
Related Studies:
Other metastatic gastrointestinal carcinoid tumor Clinical Trials
Other District of Columbia Clinical Trials
Other Washington D.C. Clinical Trials
Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors
|
|
|
|
|
|
|
|
